Community Trust & Investment Co Has Cut Holding in Pfizer (PFE) by $4.57 Million; Abbvie (ABBV) Shareholder Rothschild Asset Management Has Lifted Stake by $67.29 Million

May 26, 2018 - By Winifred Garcia

AbbVie Inc. (NYSE:ABBV) Logo

Community Trust & Investment Co decreased its stake in Pfizer Inc (PFE) by 34.79% based on its latest 2017Q4 regulatory filing with the SEC. Community Trust & Investment Co sold 127,002 shares as the company’s stock declined 3.13% with the market. The institutional investor held 238,078 shares of the health care company at the end of 2017Q4, valued at $8.62M, down from 365,080 at the end of the previous reported quarter. Community Trust & Investment Co who had been investing in Pfizer Inc for a number of months, seems to be less bullish one the $208.71B market cap company. The stock decreased 0.59% or $0.21 during the last trading session, reaching $35.68. About 14.24M shares traded. Pfizer Inc. (NYSE:PFE) has risen 2.43% since May 26, 2017 and is uptrending. It has underperformed by 9.12% the S&P500.

Rothschild Asset Management Inc increased its stake in Abbvie Inc (ABBV) by 7239.53% based on its latest 2017Q4 regulatory filing with the SEC. Rothschild Asset Management Inc bought 700,931 shares as the company’s stock declined 6.31% with the market. The institutional investor held 710,613 shares of the major pharmaceuticals company at the end of 2017Q4, valued at $68.72M, up from 9,682 at the end of the previous reported quarter. Rothschild Asset Management Inc who had been investing in Abbvie Inc for a number of months, seems to be bullish on the $160.40B market cap company. The stock decreased 2.00% or $2.06 during the last trading session, reaching $101.08. About 25.30M shares traded or 232.48% up from the average. AbbVie Inc. (NYSE:ABBV) has risen 39.20% since May 26, 2017 and is uptrending. It has outperformed by 27.65% the S&P500.

Since December 15, 2017, it had 0 insider purchases, and 13 selling transactions for $17.75 million activity. $353,677 worth of Pfizer Inc. (NYSE:PFE) was sold by LUND-JURGENSEN KIRSTEN. Dolsten Mikael sold $2.55 million worth of stock. 33,368 shares valued at $1.24 million were sold by SUSMAN SALLY on Monday, February 26. Shares for $296,560 were sold by JOHNSON RADY A. READ IAN C sold $4.76 million worth of Pfizer Inc. (NYSE:PFE) on Tuesday, May 1. CORNWELL W DON had sold 1,758 shares worth $64,679.

Community Trust & Investment Co, which manages about $800.63M US Long portfolio, upped its stake in Cbs Corp (NYSE:CBS) by 72,343 shares to 200,582 shares, valued at $11.83 million in 2017Q4, according to the filing.

Among 22 analysts covering Pfizer (NYSE:PFE), 9 have Buy rating, 1 Sell and 12 Hold. Therefore 41% are positive. Pfizer had 79 analyst reports since July 29, 2015 according to SRatingsIntel. The firm has “Buy” rating by Jefferies given on Tuesday, September 13. The stock of Pfizer Inc. (NYSE:PFE) earned “Overweight” rating by Morgan Stanley on Wednesday, September 20. Jefferies maintained the stock with “Buy” rating in Thursday, July 14 report. Jefferies maintained Pfizer Inc. (NYSE:PFE) rating on Wednesday, August 16. Jefferies has “Hold” rating and $35.0 target. BMO Capital Markets maintained the stock with “Outperform” rating in Thursday, October 19 report. The stock has “Buy” rating by Argus Research on Wednesday, July 29. The stock of Pfizer Inc. (NYSE:PFE) earned “Hold” rating by Jefferies on Thursday, July 13. The rating was maintained by SunTrust on Sunday, January 28 with “Hold”. The firm has “Hold” rating by Jefferies given on Thursday, October 26. The rating was maintained by S&P Research with “Hold” on Wednesday, October 28.

Analysts await Pfizer Inc. (NYSE:PFE) to report earnings on August, 7. They expect $0.75 EPS, up 11.94% or $0.08 from last year’s $0.67 per share. PFE’s profit will be $4.39 billion for 11.89 P/E if the $0.75 EPS becomes a reality. After $0.77 actual EPS reported by Pfizer Inc. for the previous quarter, Wall Street now forecasts -2.60% negative EPS growth.

More notable recent Pfizer Inc. (NYSE:PFE) news were published by: Seekingalpha.com which released: “Eidos Therapeutics files for initial public offering” on May 25, 2018, also Seekingalpha.com with their article: “Pfizer: Buy This Dip?” published on May 03, 2018, Streetinsider.com published: “Pfizer (PFE) Begins a Phase 1/2 Study to Evaluate RSV Vaccine” on May 22, 2018. More interesting news about Pfizer Inc. (NYSE:PFE) were released by: Seekingalpha.com and their article: “Pfizer Is A Definite Buy For 2018” published on April 30, 2018 as well as 247Wallst.com‘s news article titled: “Major Pharma Short Sellers Grow More Selective” with publication date: May 25, 2018.

Investors sentiment increased to 1.06 in Q4 2017. Its up 0.10, from 0.96 in 2017Q3. It is positive, as 51 investors sold PFE shares while 675 reduced holdings. 134 funds opened positions while 632 raised stakes. 4.07 billion shares or 0.28% more from 4.06 billion shares in 2017Q3 were reported. Ghp Invest invested 0.07% of its portfolio in Pfizer Inc. (NYSE:PFE). Gam Hldg Ag invested in 0.53% or 472,893 shares. Nbt Savings Bank N A Ny holds 201,356 shares or 1.15% of its portfolio. Court Place Limited Liability Company reported 1.17% stake. Uss Invest Mgmt Ltd invested 0.08% in Pfizer Inc. (NYSE:PFE). Marshwinds Advisory Company holds 123,352 shares. Moreover, Franklin Street Advisors Nc has 0.18% invested in Pfizer Inc. (NYSE:PFE) for 33,300 shares. 213,397 were reported by Baker Avenue Asset Mngmt Ltd Partnership. 1.05 million were accumulated by Connor Clark Lunn Investment Ltd. Catawba Cap Mgmt Va invested 1.56% in Pfizer Inc. (NYSE:PFE). Campbell Newman Asset Mngmt Incorporated has 42,778 shares for 0.26% of their portfolio. Harvey Invest Limited Liability Co, Kentucky-based fund reported 33,695 shares. Tru Of Toledo Na Oh has invested 0.71% in Pfizer Inc. (NYSE:PFE). California-based Eqis Cap Mgmt has invested 0.12% in Pfizer Inc. (NYSE:PFE). Asset Mgmt Gp Inc owns 36,566 shares for 0.48% of their portfolio.

Since December 14, 2017, it had 0 insider purchases, and 11 sales for $47.70 million activity. The insider SEVERINO MICHAEL sold $311,684. Shares for $8.57 million were sold by RICHMOND TIMOTHY J.. CHASE WILLIAM J had sold 70,928 shares worth $8.31 million. $2.95 million worth of AbbVie Inc. (NYSE:ABBV) shares were sold by Schumacher Laura J. 992 AbbVie Inc. (NYSE:ABBV) shares with value of $119,351 were sold by Michael Robert A.. Another trade for 83,574 shares valued at $9.57M was sold by ALBAN CARLOS.

Rothschild Asset Management Inc, which manages about $4.79 billion and $9.48B US Long portfolio, decreased its stake in Cummins Inc (NYSE:CMI) by 58,440 shares to 240,056 shares, valued at $42.40 million in 2017Q4, according to the filing. It also reduced its holding in American Woodmark Corp (NASDAQ:AMWD) by 8,545 shares in the quarter, leaving it with 327,147 shares, and cut its stake in Applied Matls Inc (NASDAQ:AMAT).

More notable recent AbbVie Inc. (NYSE:ABBV) news were published by: Fool.com which released: “Better Buy: Johnson & Johnson (JNJ) vs. AbbVie (ABBV)” on May 02, 2018, also Seekingalpha.com with their article: “Trump speech on drug prices light on specifics” published on May 11, 2018, 247Wallst.com published: “Major Pharma Short Sellers Grow More Selective” on May 25, 2018. More interesting news about AbbVie Inc. (NYSE:ABBV) were released by: Bizjournals.com and their article: “Chicago’s biggest companies are raking it in. Here’s what’s driving the profit boom.” published on May 26, 2018 as well as Seekingalpha.com‘s news article titled: “Premarket analyst action – healthcare” with publication date: May 24, 2018.

Among 23 analysts covering Abbvie Inc (NYSE:ABBV), 10 have Buy rating, 2 Sell and 11 Hold. Therefore 43% are positive. Abbvie Inc had 92 analyst reports since July 21, 2015 according to SRatingsIntel. The stock of AbbVie Inc. (NYSE:ABBV) has “Buy” rating given on Monday, February 26 by Jefferies. Bank of America maintained AbbVie Inc. (NYSE:ABBV) on Monday, March 26 with “Hold” rating. Credit Suisse maintained the stock with “Hold” rating in Monday, January 29 report. Credit Suisse maintained it with “Hold” rating and $7400 target in Thursday, July 20 report. Leerink Swann upgraded the stock to “Outperform” rating in Monday, October 2 report. Leerink Swann downgraded the stock to “Hold” rating in Monday, January 29 report. The stock of AbbVie Inc. (NYSE:ABBV) earned “Buy” rating by SunTrust on Wednesday, July 22. The stock of AbbVie Inc. (NYSE:ABBV) has “Buy” rating given on Monday, July 17 by Jefferies. The rating was maintained by Jefferies with “Buy” on Friday, August 18. The firm has “Equal-Weight” rating given on Thursday, April 5 by Barclays Capital.

Investors sentiment decreased to 0.8 in 2017 Q4. Its down 0.05, from 0.85 in 2017Q3. It worsened, as 42 investors sold ABBV shares while 695 reduced holdings. 139 funds opened positions while 448 raised stakes. 1.06 billion shares or 0.35% more from 1.06 billion shares in 2017Q3 were reported. Daiwa Sb Investments accumulated 1,230 shares or 0.03% of the stock. The New York-based Advent De has invested 0.07% in AbbVie Inc. (NYSE:ABBV). Sather Group owns 6,000 shares. Fidelity Natl Financial has 2.96% invested in AbbVie Inc. (NYSE:ABBV) for 207,950 shares. Tekla Mgmt holds 346,313 shares. Royal Commercial Bank Of Canada owns 0.27% invested in AbbVie Inc. (NYSE:ABBV) for 6.26M shares. 23,593 were reported by Cadinha & Ltd Liability Co. Manchester Capital Ltd Liability stated it has 6,439 shares. Chase Invest Counsel Corporation holds 2,122 shares. 1.40 million were reported by Amundi Pioneer Asset Inc. 262,537 were accumulated by Churchill Management Corp. Investors Asset Mngmt Of Georgia Ga Adv accumulated 10,317 shares. Connor Clark And Lunn Invest Mngmt Limited has invested 0.01% of its portfolio in AbbVie Inc. (NYSE:ABBV). British Columbia Management Corp holds 0.47% or 695,803 shares. Commercial Bank has invested 0.4% in AbbVie Inc. (NYSE:ABBV).

Pfizer Inc. (NYSE:PFE) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>